SEC Comment Letter 0000000000-25-003018 to BioCardia, Inc. (BCDA)
BioCardia, Inc.
Date: March 20, 2025 · CIK: 0000925741 · Accession: 0000000000-25-003018
AI Filing Summary & Sentiment
Reasoning
Letter
Re: BioCardia, Inc. Draft Registration Statement on Form S-1 Submitted March 17, 2025 CIK No. 0000925741 Dear Peter Altman:
March 20, 2025
Peter Altman Chief Executive Officer BioCardia, Inc. 320 Soquel Way Sunnyvale, California 94085
Our initial review of your draft registration statement indicates that it fails to comply with the requirements of the Securities Act of 1933, the rules and regulations thereunder and the requirements of the form. More specifically, the draft registration statement does not include audited financial statements for the fiscal year ended December 31, 2024.
We will provide more detailed comments relating to your registration statement following our review of a substantive amendment that addresses these deficiencies.
Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Austin D. March
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> March 20, 2025 Peter Altman Chief Executive Officer BioCardia, Inc. 320 Soquel Way Sunnyvale, California 94085 Re: BioCardia, Inc. Draft Registration Statement on Form S-1 Submitted March 17, 2025 CIK No. 0000925741 Dear Peter Altman: Our initial review of your draft registration statement indicates that it fails to comply with the requirements of the Securities Act of 1933, the rules and regulations thereunder and the requirements of the form. More specifically, the draft registration statement does not include audited financial statements for the fiscal year ended December 31, 2024. We will provide more detailed comments relating to your registration statement following our review of a substantive amendment that addresses these deficiencies. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Austin D. March </TEXT> </DOCUMENT>